Introduction
Vitamin D insufficiency or deficiency has increased in the general population and become an important public health issue. 1 Vitamin D is mainly known for its favorable effects in calcium and bone metabolism. However, increasing numbers of studies have established that vitamin D insufficiency contributes to a number of diseases, suggesting a range of physiological functions of vitamin D. [2] [3] [4] Several clinical studies have confirmed that vitamin D plays a crucial role in modulating innate immune responses toward various pathogens. 5 Moreover, recent studies indicate that vitamin D can regulate the adaptive immune response in various inflammatory and autoimmune diseases. 6, 7 These results suggest the beneficial effects of vitamin D supplementation in decreasing the risk and adverse outcomes of inflammatory diseases, although the precise effect remains to be elucidated in large clinical trials.
The two major physiologically relevant forms of vitamin D are vitamin D 2 (ergocalciferol) and vitamin D 3 (cholecalciferol). In humans, vitamin D 3 seems to be more effective than vitamin D 2 in maintaining the circulatory level of 25-hydroxyvitamin D 3 (25 [OH]D 3 ), a stable marker of vitamin D status. 8, 9 The main sources of vitamin D 3 are endogenous production from 7-dehydrocholesterol in the skin by ultraviolet B energy and dietary intake from foods, including egg yolk, beef liver, and milk products. 8, 9 Vitamin D 3 is metabolized to 25(OH)D 3 in the liver by vitamin D 25-hydroxylase and then further hydroxylated by the key enzyme 25-hydroxyl vitamin D 3 -1α-hydroxylase (CYP27B1) to the biologically active form: calcitriol 1,25(OH) 2 D 3 binds and activates the vitamin D receptor (VDR), a member of the superfamily of nuclear receptors and functions as a ligand-activated transcription factor. 11 It is now well recognized that CYP27B1 and VDR are expressed in cells involved in the immune/inflammation system in the human body, 12 which provides the biological basis for the role of vitamin D in inflammatory diseases.
Most clinical studies support the view that serum 25(OH)D 3 levels of less than 20 ng/mL (50 nmol/L) indicate vitamin D deficiency. Serum 25(OH)D 3 levels below 30 ng/mL indicate insufficiency, while levels between 30 and 60 ng/mL (75 and 150 nmol/L) represent normal values. 1, 13 Epidemiological studies suggest an inverse association between circulating levels of 25(OH)D 3 and inflammatory markers, including CRP and interleukin (IL)-6.
14 Supplemental vitamin D and calcium have been found to decrease the biomarkers of inflammation. 15, 16 However, a role for supplementation of vitamin D in modifying inflammatory disease has not been well defined, and it is unclear at present whether vitamin D status is causally related to the pathogenesis of the disease or is merely a marker of health. 17 This review summarizes and critically evaluates the data from preclinical, epidemiological, and interventional studies in order to elucidate the role and mechanisms of vitamin D in inflammatory diseases.
Vitamin D signaling and immune/inflammation system
VDR expression has been documented in macrophages, a crucial cell type in the innate immune response. 18 In macrophages, activation of the toll-like receptor (TLR1/2) heterodimer by Mycobacterium tuberculosis results in the upregulation of VDR and CYP27B1, leading to induction of the antimicrobial peptide cathelicidin and the killing of intracellular M. tuberculosis. 19 In this process, IL-15 links TLR2/1-induced macrophage differentiation to the vitamin D-dependent antimicrobial pathway. 20 The increase of CYP27B1 results in the accumulation of 1,25(OH) 2 D 3 , which further activates VDR, leading to the target gene transcription via vitamin D response elements located in the regulatory regions of 1,25(OH) 2 D 3 target genes. 21 Chen et al 22 found that 1,25(OH) 2 D 3 can regulate TLR signaling via stimulating SOCS1 by downregulating miR-155 in macrophages, which provide a novel negative feedback regulatory mechanism for vitamin D to control innate immunity. In a recent study, both forms of vitamin D -1,25(OH) 2 D 3 and 25(OH)D 3 -dose-dependently inhibited lipopolysaccharide-induced p38 phosphorylation, IL-6, and TNFα production by human monocytes via histone H4 in an acetylation-dependent manner. 23 Moreover, 1,25(OH) 2 D 3 or its analogs have been shown to initiate the differentiation of myeloid progenitors into macrophages, 24 and to reduce MCP-1 and IL-6 expression via inhibiting the activation of NF-κB in macrophages. 25 In addition, Vitamin D has been thought to be a natural endoplasmic reticulum stress reliever, 26 and can selectively suppress key effector functions of interferon (IFN)-γ-activated macrophages. 27 Interestingly, in the presence of 1,25(OH) 2 D 3 , VDR has also been found to repress gene transcription via displacing the deoxyribonucleic acid-bound nuclear factor of activated T-cells, thus repressing inflammatory cytokine expression 28 ( Figure 1 ). Dendritic cells (DCs) are the most potent antigenpresenting cells. A number of studies have shown that 1,25(OH) 2 D 3 inhibits the differentiation, maturation, and immunostimulatory capacity of human DCs, characterized as the tolerogenic properties, in a VDR-dependent manner. 29, 30 Molecular mechanisms underlying the modulation of tolerogenic properties of DCs by 1,25(OH) 2 D 3 include decreasing surface expression of major histocompatibility complex II and costimulatory molecules (CD40, CD80, CD86), upregulating inhibitory immunoglobulinlike transcript 3 molecules, and enhancing secretion of chemokine (C-C motif) ligand 22 and IL-10 29,31 ( Figure 2 ). The enhancement of DC tolerogenicity by 1,25(OH) 2 D 3 results in the induction of T-regulatory cells, a critical event for suppressing the inflammatory response of T-effector cells. 31 1,25(OH) 2 D 3 also acts directly with VDR on the T lymphocyte to inhibit its proliferation. 32 Although native T-cells did not express VDR, VDR expression was induced by T-cell antigen-receptor signaling via the alternative p38 MAPK pathway, which is crucial for T-cell antigen-receptor responsiveness in naïve T-cells. 33 Recent work has revealed that 1,25(OH) 2 VDR-knockout mice developed an unaltered Th1 response to infection due to impaired upregulation of arginase 1 expression under Leishmania infection. 45 Although 1,25(OH) 2 D 3 inhibits the proliferation and differentiation of both T and B lymphocytes, the central mechanism underlying microbial eradication of vitamin D seems to be the inhibition of activation of TLRs in the host cell, which induces the formation of potent antimicrobial peptides. 19, 50 The additional 51 However, these associations were not found in symptomatic patients. 52 In a randomized controlled trial of vitamin D supplements (1,400 IU/week) in infants, there were no differences in plasma levels of CRP or inflammatory cytokines between the treatment group and the control group. 53 The exact effects and mechanisms of vitamin D in infectious diseases therefore require further study.
The functioning of VDR is affected by gene polymorphisms, in which a start codon polymorphism (rs2228570) and three polymorphisms in the 3′ untranslated region (UTR) of the VDR gene (rs1544410, rs7975232, and rs731236) are the most commonly studied polymorphisms in the VDR gene. 54 There are reports that VDR polymorphism is linked to increased susceptibility to infection. Alagarasu et al have found that the frequency of the C/C genotype of rs7975232 was significantly lower in dengue virus infection patients (DEN) compared to health controls. 54 Aslan et al examined VDR gene polymorphisms in urinary tract infections, and found that the ff genotype in rs2228570 was significantly increased in UTI children with urinary tract infection. 55 Rathored et al have also found that the patients with ff genotypes in rs2228570 were at high risk of multidrugresistant tuberculosis with smear-positive disease. 56 In a multicenter clinical trial, Levin et al recently investigated the relationship of common variation within genes encoding the vitamin D-binding protein, megalin, cubilin, CYP27B1, CYP24A1, and VDR with low 25(OH)D levels, and found some minor alleles at rs7968585 and rs7968585 within the VDR gene that were related to low 25(OH)D 3 . 57 The results of these studies suggest that VDR gene polymorphisms can be important for the susceptibility of inflammatory diseases, which may be due to the lower 25(OH)D 3 status affected by VDR gene polymorphisms.
Atherosclerosis-related cardiovascular disease
It is well known that inflammation plays a key role in the development of atherosclerosis. Inflammatory cells, mainly macrophages and T lymphocytes, produce a wide range of inflammatory cytokines in atherosclerotic lesions, which are critically important in the progression of atherosclerosis-related cardiovascular disease (CVD). 58 Numerous studies have verified vitamin D deficiency (25[OH]D 3 ,20 ng/mL) as one of the new risk factors for coronary heart disease (CHD). 59, 60 Many potential functions of vitamin D -including protection of endothelial function, inhibition of smooth-muscle cell (SMC) proliferation, improvement of lipid profile, and others -have been thought to contribute to the antiatherogenic effect of vitamin D. [61] [62] [63] Clinical studies have indicated an inverse association between 25(OH)D 3 levels and CHD risk ( Table 2) . Three large retrospective studies demonstrated that 25(OH)D 3 levels below 20 ng/mL are associated with increased risk for CHD, including hypertension, diabetes mellitus, obesity, high serum low-density lipoprotein (LDL), triglyceride (TG), and low high-density lipoprotein (HDL) levels. 17, 64, 65 Several cross-sectional prospective studies further strengthened this evidence, which demonstrated a significant increase for allcause mortality when serum 25(OH)D 3 levels were less than 30 ng/mL. [66] [67] [68] [69] [70] In a population-based cohort study, Lim et al 71 reported that a low 25(OH)D 3 concentration had a higher risk of significant coronary artery stenosis. The odds ratios were 2.08 for 25(OH)D 3 concentration of 15-29.9 ng/mL versus at least 30 ng/mL and 3.12 for 25(OH)D 3 concentration below 15 ng/mL versus at least 30 ng/mL. Although observational studies suggest that vitamin D deficiency or insufficiency is related to a higher risk for CVD, data from recent RCTs designed to assess the impact of vitamin D supplementation on cardiovascular outcomes are conflicting (Table 3 ). Some RCT results have shown that a higher intake of vitamin D is associated with a lower risk of CVD, especially in men, due to the improvement of vascular endothelial function and decrease in inflammation. [72] [73] [74] However, most evidence at present shows that vitamin supplementation has no effect on vascular disease mortality or all-cause mortality. [73] [74] [75] [76] [77] [78] Since large well-controlled double-blinded RCTs aiming primarily for cardiovascular end points are still absent, whether or not vitamin D supplementation can significantly improve cardiovascular outcomes is largely unknown. At this time, larger RCTs, which can be used to evaluate the application of vitamin D in cardiology, have yet to be implemented.
The regulation of the immune/inflammatory response is one of the most verified mechanisms of the antiatherogenic effect of vitamin D. First, vitamin D exerts protective effects against endothelial dysfunction, an inflammatory process that precedes atherosclerosis, via multiple mechanisms, including stimulating nitric oxide production and inhibiting oxidative stress. 59, 79 Vitamin D has been found to inhibit contractions, which were endothelium-dependent through inhibiting cyclooxygenase-1 expression and reactive oxygen species production. 59, 79 In addition, calcitriol significantly repressed the expression of cyclooxygenase 2 and promoted 
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Yin and Agrawal prostaglandin catabolism, both of which reduce the level of prostaglandins and suppress proinflammatory cytokine expression in endotheliocytes. 80 Second, 1,25(OH) 2 D 3 may alter macrophage function and gene expression, which is crucial in the formation of foam cells and vascular inflammation response that promote the process of atherosclerosis. 26 In patients with type 2 diabetes mellitus, 1,25(OH) 2 D 3 can inhibit foam-cell formation, and suppresses macrophage cholesterol uptake via reducing peroxisome proliferated-activated receptor-γ-dependent CD36 expression. 81 In addition, vitamin D induces an antiatherogenic monocyte/macrophage phenotype via regulating endoplasmic reticulum stress. 26 Previous studies by our group have found vitamin D deficiency causes increased proinflammatory cytokine expression in epicardial adipose tissue, which is coupled with increased inflammatory cellular infiltrate, suggesting the anti-inflammation effect of vitamin D in epicardial adipose tissue is a novel mechanism for atheroprotection. 82 Third, 1,25(OH) 2 D 3 inhibits the proliferation of vascular SMCs (VSMCs), 83 and exerts protective effects against VSMC morphological changes, which further inhibit the secretion of inflammatory molecules. 84 In a hypercholesterolemic swine model, our group has found that vitamin D deficiency significantly increases the expression of TNFα in neointimal lesions after balloon angioplasty and that calcitriol has antiproliferative properties in TNFα-stimulated human VSMCs. 85 Besides the direct antiatherogenic effect, vitamin D has a variety of indirect effects on the systemic pathophysiological conditions that promote atherosclerosis, such as improving insulin resistance and hypertension. 59 However, Ponda et al 17, 77 recently reported repletion of 25(OH)D 3 levels in the short term does not correct or even ameliorate dyslipidemia, suggesting that the definitive role of vitamin D in CVD remains to be elucidated.
Asthma
Asthma is a disorder characterized by varying and recurring symptoms of airflow obstruction and bronchial hyperresponsiveness in the setting of inflammation. 86 Epidemiologic studies suggest an association between vitamin D deficiency and asthma (Table 4) . [87] [88] [89] [90] [91] [92] Some prospective studies and case-control studies have shown the majority of asthmatic children to be vitamin D-deficient. 91, 93 Vitamin D deficiency has been found to increase the risk of severe asthma exacerbation, defined as the need for emergency room evaluation or hospitalization. 94 A prospective study of adults and children found that low serum 25(OH)D 3 levels were associated with increased requirement of steroids in the pediatric asthma group. 90 Higher maternal circulating 25(OH)D 3 concentrations in pregnancy were independently associated with lower risk of asthma at 5 years old in offspring. 92 However, another study showed that high 25(OH)D 3 levels in pregnant women could pose an increased risk of asthma in offspring, 95 indicating a reasonable level of vitamin D in pregnant women is crucial for maintaining normal bronchial responsiveness in offspring.
The mechanisms of vitamin D deficiency in asthma pathophysiology are not fully understood. Many researchers have focused on the potential effect of vitamin D in inflammatory response that inhibits the progress of asthma. 86 Vitamin D has been found to increase the production of IL-10, an anti-inflammatory cytokine, while decreasing the expression of proinflammatory cytokines in airway SMCs. 96, 97 In a mouse model, Gorman et al 98 recently examined asthma-like responses 24 hours after airway challenge with the experimental allergen ovalbumin in adult offspring born to vitamin D 3 -replete and vitamin D 3 -deficient mothers. They found the ability of airway-draining lymph-node cells to proliferate and secrete cytokines in response to ovalbumin ex vivo was significantly enhanced by vitamin D deficiency. 98 In a mouse model of allergic airway inflammation, our group has previously found vitamin D deficiency causes an increase in the expression of TNFα, which decreases the expression of VDR and prohibitin, a vitamin D target gene. 95 Vitamin D supplementation reduces the levels of TNFα, thereby increasing the expression of VDR and prohibitin, which could be responsible for reducing allergic airway inflammation. 99 
Inflammatory bowel diseases
Vitamin D deficiency is common in patients with inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn's disease (CD) [100] [101] [102] [103] [104] [105] (Table 5 ). Several retrospective and cross-sectional studies have reported a high prevalence of vitamin D deficiency in patients with IBD, which was associated with disease activity and quality of life. [101] [102] [103] [104] [105] Recently, a prospective cohort study of 72,719 women enrolled in the Nurses' Health Study examined the relationship between vitamin D status and risk of CD and UC. 100 Vitamin D supplementation has shown potential therapeutic benefit for IBD in some small, randomized, double-blind studies (Table 5 109 Although most studies have now shown vitamin D 3 treatment might be effective in IBD, larger, randomized, double-blind, placebo-controlled trials needed to elucidate this correlation are lacking.
In VDR-knockout mice models, vitamin D deficiency increases susceptibility to dextran sodium sulfate-induced colitis. 110 Histological examination revealed the disruption in the epithelial junctions in dextran sodium sulfate-treated VDR -/-mice. 1,25(OH) 2 D 3 preserved the integrity of the tight junctions in Caco-2 cell monolayers. 110 
Chronic kidney disease
Normal renal function is crucial for vitamin D metabolism. 1 Vitamin D deficiency is highly prevalent among patients with chronic kidney disease (CKD; 20%-85%). 112, 113 Studies have demonstrated a strong association between vitamin D deficiency and increased all-cause and CKD mortality in the general population (Table 6) . [113] [114] [115] [116] [117] [118] Chronic low-grade inflammation is a hallmark of CKD, and has been disclosed as one important factor contributing to the progression of CKD and high cardiovascular mortality. 10 A prospective cohort study of 444 patients with eGFR ,60 mL/min/1.73 m 2 (follow-up time 9.4 years) showed that most patients died from cardiovascular causes. 116 Another cross-sectional study strengthened this evidence, demonstrating that higher vascular stiffness and endothelial dysfunction were associated with low levels of 25(OH) D 3 and 1,25(OH) 2 D 3 in CKD patients. 119 Vitamin D intake for more than 12 months can significantly reduce the probability of cardiovascular events. 117 Low 25(OH)D 3 and 1,25(OH) 2 D 3 levels are independently associated with albuminuria, a major risk factor for the progression of renal disease linked to all-cause mortality and cardiovascular mortality. 114 Treatment with active vitamin D preparations also has a beneficial effect in decreasing albuminuria. 120 Besides regulating inflammation and proteinuria, vitamin D has been found to improve aerobic capacity and increase the level of fetuin-A, an important protective factor for cardiovascular morbidity in pediatric CKD patients. 115, 121 Several randomized, double-blind, placebo-controlled studies have examined the role of vitamin D as a therapeutic agent for CKD (Table 7) . 120, [122] [123] [124] [125] [126] [127] High-dose cholecalciferol supplementation (50,000 IU/week for 12 weeks) was safe and sufficient to maintain serum 25(OH)D 3 concentrations ($30 ng/mL) and simultaneously decreased serum MCP-1 concentrations in early CKD. [122] [123] [124] In moderate CKD patients, both cholecalciferol (vitamin D 3 ) and ergocalciferol (vitamin D 2 ) are effective in increasing 25(OH)D 3 and decreasing parathyroid hormone and inflammatory cytokine levels. 125, 127 In nonhemodialysis patients, supplementation of cholecalciferol with 40,000 IU/week for 8 weeks significantly increased the level of 1,25(OH) 2 D 3 and decreased serum parathyroid hormone and inflammatory cytokine levels. 126 However, this effect was not observed in end-stage renal disease (ESRD) patients. 126 As patients with CKD progress to ESRD, renal CYP27B1 activity decreases, resulting in the impaired formation of 1,25(OH) 2 D 3 in many of these patients. 128 Previous attempts to counteract these changes in mineral metabolism with nutritional vitamin D therapy have been unsuccessful. 129 For this reason, most therapeutic approaches to treat vitamin D deficiency in ESRD patients favor the use of calcitriol or its associated analogs instead of the use of nutritional vitamin D forms. 128, 130 Interestingly, in an uncontrolled trial of seven ESRD patients, Stubbs et al 128 reported significant and favorable effects after 8 weeks of cholecalciferol supplementation on circulating monocytes and concentration of inflammatory cytokines, which may be have been due to extrarenal production of calcitriol in the setting of minimal renal CYP27B1 activity in ESRD patients.
Experimental studies have demonstrated that vitamin D can control inflammation and oxidative stress that prevent CKD progress. 131, 132 Using a mouse model of obstructed nephropathy, Tan et al 132 reported that the synthetic vitamin D analog paricalcitol reduced the infiltration of inflammatory T-cells and macrophages in the obstructed kidney, which was accompanied by a decreased expression of RANTES and TNFα. In a human proximal tubular cell line (HKC-8), paricalcitol inhibited RANTES messenger ribonucleic acid and protein expression and abolished the ability of tubular cells to recruit lymphocytes and monocytes after TNFα stimulation. 132 In a study using a uremic rat model, paricalcitol significantly decreased cardiac oxidative stress. When combining with the angiotensin-converting enzyme inhibitor enalapril, paricalcitol further prevented inflammation and oxidative injury in uremic rats. 131 These studies provide experimental evidence supporting the role of inflammation in providing a pathological link between vitamin D and CKD.
Liver inflammatory disease
Nonalcoholic fatty liver disease (NAFLD) refers to the presence of hepatic steatosis without significant alcohol use or other known liver disease, and is characterized by chronic portal inflammation. 133 Recent studies emphasize the role of insulin resistance, metabolic syndrome, and proinflammatory cytokines in the development and progression of NAFLD. 134, 135 Vitamin D serum levels negatively correlate with insulin resistance and metabolic syndrome. Supplementation of vitamin D has been found to reduce 
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Yin and Agrawal insulin resistance in obese children. 134 Recently, lower vitamin D levels were found to be independently associated with increased severity of steatosis, necroinflammation, and fibrosis in NAFLD. 136, 137 Furthermore, serum vitamin D levels that could predict the severity of NAFLD independently of other metabolic characteristics and relate vitamin D to NAFLD are largely unknown. Considering that inflammation is followed by steatosis in most NAFLD patients, 138 vitamin D may be involved in NAFLD through its ability to modulate the immune/inflammation system. Recently, Roth et al 139 fed young (25-day-old) Sprague Dawley rats with a low-fat diet alone, with vitamin D depletion, or with a Westernized diet, and found that vitamin D-depleted animals fed a Westernized diet exhibited significantly greater hepatic steatosis and inflammation compared to low-fat diet groups, which may be related to the upregulation of TLR2, TLR4, TLR9, and endotoxin receptor CD14 in the liver, suggesting vitamin D depletion exacerbates NAFLD, possibly by way of endotoxin exposure in a Westernized diet rat model. Low vitamin D serum levels have also been found to correlate with the severity of inflammation and fibrosis in chronic hepatitis B and C viruses, where cellular immunity played crucial roles in the progress of diseases. 140, 141 In hepatitis B, VDR polymorphisms have been associated with infection susceptibility and clinical course in different populations. 142 Taken together, these data indicate a potential link between vitamin D and viral hepatitis.
Multiple sclerosis
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system, which affects more than 2 million individuals worldwide. Growing evidence suggest that vitamin D deficiency might be one of the most important environmental factors for the prevalence, relapse rate, and progression of MS [143] [144] [145] [146] (Table 8 ). In a large prospective case-control study of 7 million US military personnel, high circulating levels of 25(OH)D 3 were found to be associated with a lower risk of MS, in which every 50 nmol/L increase in serum 25(OH)D 3 led to a 41% decrease in MS risk. 145 Another prospective study of 35,794 mothers of participants in the Nurses' Health Study II has shown that the relative risk of MS was lower among women born to mothers with high milk or vitamin D intake during pregnancy. 147 In addition, serum 25(OH)D 3 concentrations in patients with MS were also found to be related to the relapse of the disease. Mowry et al found that each 10 ng/mL increase in 25(OH)D 3 level was associated with a 15% lower risk of a new T 2 lesion and a 32% lower risk of a gadolinium-enhancing lesion.
Each 10 ng/mL increase in vitamin D level was associated with lower subsequent disability, suggesting higher vitamin D levels were associated with lower relapse risk. 143 Although a link between vitamin D supplementation and decreased risk of MS has been widely assumed, present vitamin D-repletion therapies have not yet shown a significant effect on the progress of MS (Table 8) . In a retrospective cohort study of 116,671 female registered nurses, intake of vitamin D ($400 IU/day) from multivitamins was not been found to statistically reduce the risk of MS. 145 Moreover, no published RCTs of vitamin D repletion so far -low dose or high dose -have shown any benefit on relative risk of MS relapse. [148] [149] [150] However, in a high-dose vitamin D 3 -supplementation RCT (20,000 IU/day for 12 weeks) in MS patients, vitamin D was found to increase proportion of IL-10 + CD4 + T-cells and decrease the ratio between IFNγ + and IL-4 + CD4 + T-cells. 151 Moreover, in a myelin oligodendrocyte glycoprotein-induced animal model of MS, vitamin D significantly attenuated central nervous system inflammation and demyelination, accompanied by a lower amount of IFNγ-producing myelin oligodendrocyte glycoprotein-specific T-cells via a developmental stagedependent manner. 152 These results suggest the exact effect of vitamin D repletion on the risk of MS remains to be clarified, since large, high-quality, randomized trials are still lacking.
Other inflammation/ immune-related disorders
Inflammation has also been found to play an important role in other chronic diseases, including hypertension, diabetes, chronic lower-back pain (CLBP), and congestive heart failure (HF). Several reviews have thoroughly discussed the relationship between vitamin D and hypertension or diabetes. 153, 154 There is clear evidence to support an association between low plasma levels of 25(OH)D 3 and hypertension and type 2 diabetes. 153, 154 Furthermore, clinical trials aimed at testing the effect of vitamin D supplementation on hypertension and type 2 diabetes documented a dose-dependent blood pressure-lowering and insulin sensitivity-increasing effect of vitamin D in patients. [155] [156] [157] However, in a recent randomized, double-blind, placebo-controlled clinical trial, high-dose oral vitamin D 3 (100,000 IU) for 6 months seemed not to reduce blood pressure or left ventricular mass in patients with resistant hypertension. 158 Because the 6-month period used in this study may have been too short a period to detect meaningful effects of vitamin D on left ventricular mass and function, longer trials and detailed studies are needed to better 
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Yin and Agrawal investigate the definite role of vitamin D supplementation in various forms of hypertension. Nonspecific lower-back pain is one of the most common reasons for CLBP that burdens health care systems with high cost. Human population studies have shown that plasma levels of vitamin D are inversely associated with risk for CLBP. 159 However, results from a double-blind RCT of 53 patients aged 18-40 years with nonspecific CLBP showed no significant effect of vitamin D supplementation (50,000 IU) in decreasing the pain visual analog scale score of the patients. 160 Vitamin D deficiency is associated with loss of muscle strength and poor outcomes in patients with HF. In a double-blind RCT in 31 patients (25[OH]D 3 levels #37.5 ng/mL), vitamin D 3 repletion (50,000 IU) decreased aldosterone in patients with HF and low serum vitamin D, suggesting that vitamin D may be an important adjunct to standard HF therapy. 161 Apart from inflammatory disorders, vitamin D deficiency has been found to be associated with immune-related disorders, such as rheumatoid arthritis and systemic lupus erythematosus. 162, 163 Randomized placebo-controlled trials have shown that vitamin D supplementation seems to ameliorate inflammatory and hemostatic markers and show a tendency toward subsequent clinical improvement in these diseases. 146, 163, 164 In a healthy population, vitamin D levels were significantly higher in antinuclear antibody-negative individuals than antinuclear antibody-positive individuals. 165 Along with this finding is the additional observation that vitamin D deficiency is associated with certain immune abnormalities in such autoimmune disorders as systemic lupus erythematosus and rheumatoid arthritis. 163, 166 Recently, a retrospective crosssectional study showed the risk of auto-and cellular immune abnormalities is increased in women with recurrent pregnancy losses and vitamin D deficiency. 167 
Conclusion
The remarkable expression of the CYP27B1 and VDR genes by macrophages, DCs, and T lymphocytes suggests that the immune/inflammation system could be a target for the effect of vitamin D. Emerging evidence from clinical studies has indicated that vitamin D deficiency is associated with several inflammatory diseases; however, the question remains whether or not vitamin D deficiency contributes to the etiology of inflammatory disease or if vitamin D deficiency is simply a manifestation of these diseases. In acute infection and autoimmune disorders, preliminary evidence suggests an important role of vitamin D supplementation in decreasing the risk of disease. The pathophysiological process in many chronic inflammatory diseases, including atherosclerosis, is complex and confounded by various metabolic factors. Whether vitamin D supplementation is beneficial in the prognosis of these diseases requires further evaluation in larger prospective trials with a focus on major outcome events. In addition, dose-response randomized trials are necessary to identify threshold effects and possible adverse effects in vitamin D therapy. Future studies should aim to characterize optimal ranges of vitamin D status following vitamin D therapy, and should focus on determining the exact relationship between vitamin D dose and outcomes during the progression of diseases.
The identification and characterization of the molecular mechanisms responsible for recognizing and responding to vitamin D in the immune/inflammation system has widened our view of the essential components of a healthy immune response. Nonetheless, many key questions remain to be addressed. These include the cell type-specific roles of VDR in the progression of inflammatory diseases and the mechanisms of cross talk between VDR and other nuclear receptors, such as the retinoid X receptor and liver X receptor, which stimulate the intracellular pathway to exert the anti-inflammation effect. In addition, a single measurement of serum vitamin D status or the current standard value is unlikely to be valid in all situations. The development of research to refine existing biomarkers or establish new indicators that takes many factors into account and to identify useful functional biomarkers of vitamin D status in specific tissues will offer key insights into the development of targeted therapies for individuals with functional vitamin D insufficiency or deficiency in inflammatory diseases, though the research methodology for these potential biomarkers remains to be elucidated.
